Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study

Abstract Background Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery. The choice of antithrombotic agents for venous thromboembolism (VTE) prevention after TKA...

Full description

Bibliographic Details
Main Authors: Li-Bo Zhou, Chao-Chao Wang, Lan-Tao Zhang, Tao Wu, Guo-Qiu Zhang
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Musculoskeletal Disorders
Subjects:
Online Access:https://doi.org/10.1186/s12891-022-06117-8
_version_ 1797958808188747776
author Li-Bo Zhou
Chao-Chao Wang
Lan-Tao Zhang
Tao Wu
Guo-Qiu Zhang
author_facet Li-Bo Zhou
Chao-Chao Wang
Lan-Tao Zhang
Tao Wu
Guo-Qiu Zhang
author_sort Li-Bo Zhou
collection DOAJ
description Abstract Background Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery. The choice of antithrombotic agents for venous thromboembolism (VTE) prevention after TKA is controversial. Therefore, this study aimed to compare the effects of different antithrombotic agents on patients after primary unilateral TKA in the context of applied TXA. Methods A total of 180 patients undergoing primary unilateral TKA from October 2020 to December 2021 were included in this study. All patients were given an intraoperative drip of 60 mg/kg TXA. Thereafter, patients were divided into three groups (n = 60 each). Baseline data were comparable among the three groups. The average follow-up time was 3.02 ± 0.09 months. Group 1 enrolled patients receiving oral rivaroxaban (RA) at 10 mg, Group 2 included patients who received subcutaneous Dalteparin sodium at 2500 IU, while Group 3 included patients taking oral aspirin (ASA) at 100 mg. Patients in all the three groups received treatment once a day for 30 days at 12 h postoperatively. The primary outcomes in this study were post-treatment drainage volume and thrombotic complication rate. The secondary outcomes included hematologic parameters, transfusion rate, intraoperative blood loss, total blood loss (TBL), and bleeding complication rate. Results The average drainage volume after treatment was significantly lower in Group 3 than in Group 1 and Group 2 (205.2 ± 69.0 vs 243.4 ± 72.5 vs 295.4 ± 72.5 ml, P < 0.001), and there was a significant difference between Group 1 and Group 2 (243.4 ± 72.5 mL vs 295.4 ± 72.5 mL, P < 0.001). The blood transfusion rate of Group 2 dramatically increased compared with Group 1 and Group 3 (20.0% vs 6.7% vs 5.0%, P = 0.01). The bleeding complication rate in Group 1 apparently increased relative to Group 2 and Group 3 (26.7% vs 10.0% vs 8.3%, P = 0.008). Besides, there was no significant difference in the thrombotic complication rate among the three groups. Conclusion Under the background of TXA application, ASA, RA, and Dalteparin sodium were all effective on preventing VTE after TKA. In addition, ASA effectively reduced post-treatment Hemoglobin (Hb) loss, drainage volume, TBL, transfusion rate, and bleeding complications compared with RA and Dalteparin sodium. Trial registration The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2200060169). Date of Registration: 21/05/2022.
first_indexed 2024-04-11T00:25:06Z
format Article
id doaj.art-7023ccb1d6c647c6920ab53e8004a73d
institution Directory Open Access Journal
issn 1471-2474
language English
last_indexed 2024-04-11T00:25:06Z
publishDate 2023-01-01
publisher BMC
record_format Article
series BMC Musculoskeletal Disorders
spelling doaj.art-7023ccb1d6c647c6920ab53e8004a73d2023-01-08T12:03:17ZengBMCBMC Musculoskeletal Disorders1471-24742023-01-012411910.1186/s12891-022-06117-8Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized studyLi-Bo Zhou0Chao-Chao Wang1Lan-Tao Zhang2Tao Wu3Guo-Qiu Zhang4Department of Graduate School, Qinghai UniversityDepartment of Bone and Joint Surgery, Affiliated Hospital of Qinghai UniversityDepartment of Bone and Joint Surgery, Affiliated Hospital of Qinghai UniversityDepartment of Bone and Joint Surgery, Affiliated Hospital of Qinghai UniversityDepartment of Bone and Joint Surgery, Affiliated Hospital of Qinghai UniversityAbstract Background Tranexamic acid (TXA) has been widely applied in total knee arthroplasty (TKA) to significantly reduce perioperative blood loss and improve knee function recovery in patients after surgery. The choice of antithrombotic agents for venous thromboembolism (VTE) prevention after TKA is controversial. Therefore, this study aimed to compare the effects of different antithrombotic agents on patients after primary unilateral TKA in the context of applied TXA. Methods A total of 180 patients undergoing primary unilateral TKA from October 2020 to December 2021 were included in this study. All patients were given an intraoperative drip of 60 mg/kg TXA. Thereafter, patients were divided into three groups (n = 60 each). Baseline data were comparable among the three groups. The average follow-up time was 3.02 ± 0.09 months. Group 1 enrolled patients receiving oral rivaroxaban (RA) at 10 mg, Group 2 included patients who received subcutaneous Dalteparin sodium at 2500 IU, while Group 3 included patients taking oral aspirin (ASA) at 100 mg. Patients in all the three groups received treatment once a day for 30 days at 12 h postoperatively. The primary outcomes in this study were post-treatment drainage volume and thrombotic complication rate. The secondary outcomes included hematologic parameters, transfusion rate, intraoperative blood loss, total blood loss (TBL), and bleeding complication rate. Results The average drainage volume after treatment was significantly lower in Group 3 than in Group 1 and Group 2 (205.2 ± 69.0 vs 243.4 ± 72.5 vs 295.4 ± 72.5 ml, P < 0.001), and there was a significant difference between Group 1 and Group 2 (243.4 ± 72.5 mL vs 295.4 ± 72.5 mL, P < 0.001). The blood transfusion rate of Group 2 dramatically increased compared with Group 1 and Group 3 (20.0% vs 6.7% vs 5.0%, P = 0.01). The bleeding complication rate in Group 1 apparently increased relative to Group 2 and Group 3 (26.7% vs 10.0% vs 8.3%, P = 0.008). Besides, there was no significant difference in the thrombotic complication rate among the three groups. Conclusion Under the background of TXA application, ASA, RA, and Dalteparin sodium were all effective on preventing VTE after TKA. In addition, ASA effectively reduced post-treatment Hemoglobin (Hb) loss, drainage volume, TBL, transfusion rate, and bleeding complications compared with RA and Dalteparin sodium. Trial registration The trial was registered at the Chinese Clinical Trial Registry (ChiCTR2200060169). Date of Registration: 21/05/2022.https://doi.org/10.1186/s12891-022-06117-8Total knee arthroplastyTranexamic acidRivaroxabanDalteparin sodium; AspirinVenous thromboembolism
spellingShingle Li-Bo Zhou
Chao-Chao Wang
Lan-Tao Zhang
Tao Wu
Guo-Qiu Zhang
Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study
BMC Musculoskeletal Disorders
Total knee arthroplasty
Tranexamic acid
Rivaroxaban
Dalteparin sodium; Aspirin
Venous thromboembolism
title Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study
title_full Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study
title_fullStr Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study
title_full_unstemmed Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study
title_short Effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement: a prospective randomized study
title_sort effectiveness of different antithrombotic agents in combination with tranexamic acid for venous thromboembolism prophylaxis and blood management after total knee replacement a prospective randomized study
topic Total knee arthroplasty
Tranexamic acid
Rivaroxaban
Dalteparin sodium; Aspirin
Venous thromboembolism
url https://doi.org/10.1186/s12891-022-06117-8
work_keys_str_mv AT libozhou effectivenessofdifferentantithromboticagentsincombinationwithtranexamicacidforvenousthromboembolismprophylaxisandbloodmanagementaftertotalkneereplacementaprospectiverandomizedstudy
AT chaochaowang effectivenessofdifferentantithromboticagentsincombinationwithtranexamicacidforvenousthromboembolismprophylaxisandbloodmanagementaftertotalkneereplacementaprospectiverandomizedstudy
AT lantaozhang effectivenessofdifferentantithromboticagentsincombinationwithtranexamicacidforvenousthromboembolismprophylaxisandbloodmanagementaftertotalkneereplacementaprospectiverandomizedstudy
AT taowu effectivenessofdifferentantithromboticagentsincombinationwithtranexamicacidforvenousthromboembolismprophylaxisandbloodmanagementaftertotalkneereplacementaprospectiverandomizedstudy
AT guoqiuzhang effectivenessofdifferentantithromboticagentsincombinationwithtranexamicacidforvenousthromboembolismprophylaxisandbloodmanagementaftertotalkneereplacementaprospectiverandomizedstudy